CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses
- 1 August 2019
- Vol. 37 (36) , 5382-5389
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 40 references indexed in Scilit:
- A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in agingVaccine, 2012
- A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+ CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adultsVaccine, 2009
- Influenza PR8 HA-specific Fab fragments produced by phage display methodsBiochemical and Biophysical Research Communications, 2008
- Recognition of microorganisms and activation of the immune responseNature, 2007
- Pathogen Recognition and Innate ImmunityCell, 2006
- Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccineVaccine, 2004
- Estimating Deaths Due to Influenza and Respiratory Syncytial VirusJAMA, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvantsEuropean Journal of Immunology, 1997
- Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990Epidemiology and Infection, 1996